Last reviewed · How we verify
NVP-1203-R
NVP-1203-R is a small molecule that targets the PD-1 receptor.
NVP-1203-R is a small molecule that targets the PD-1 receptor. Used for Non-small cell lung cancer, PD-L1 positive.
At a glance
| Generic name | NVP-1203-R |
|---|---|
| Sponsor | NVP Healthcare |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
By binding to PD-1, NVP-1203-R prevents the interaction between PD-1 and its ligands, leading to the activation of T cells and enhanced anti-tumor immune response.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
Common side effects
- Pneumonitis
- Hypothyroidism
Key clinical trials
- Efficacy and Safety of NVP-1203 and NVP-1203-R in Patients With Acute Low Back Pain (PHASE3)
- Efficacy and Safety of NVP-1203 in Patients With Acute Low Back Pain (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NVP-1203-R CI brief — competitive landscape report
- NVP-1203-R updates RSS · CI watch RSS
- NVP Healthcare portfolio CI